Zymeworks (ZYME) Competitors $13.46 0.00 (0.00%) As of 09:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock ZYME vs. ACAD, ACLX, SRRK, VKTX, PTCT, MLTX, SWTX, PTGX, AAPG, and IMVTShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), Scholar Rock (SRRK), Viking Therapeutics (VKTX), PTC Therapeutics (PTCT), MoonLake Immunotherapeutics (MLTX), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors ACADIA Pharmaceuticals Arcellx Scholar Rock Viking Therapeutics PTC Therapeutics MoonLake Immunotherapeutics SpringWorks Therapeutics Protagonist Therapeutics Ascentage Pharma Group International Immunovant ACADIA Pharmaceuticals (NASDAQ:ACAD) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of ACAD or ZYME? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ACAD or ZYME? ACADIA Pharmaceuticals presently has a consensus target price of $28.13, suggesting a potential upside of 24.17%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.71Zymeworks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ACAD or ZYME more profitable? ACADIA Pharmaceuticals has a net margin of 22.97% compared to Zymeworks' net margin of -121.73%. ACADIA Pharmaceuticals' return on equity of 17.46% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals22.97% 17.46% 10.75% Zymeworks -121.73%-26.83%-20.39% Does the media prefer ACAD or ZYME? In the previous week, ACADIA Pharmaceuticals had 12 more articles in the media than Zymeworks. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 0 mentions for Zymeworks. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Zymeworks' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment ACADIA Pharmaceuticals Positive Zymeworks Neutral Which has more risk & volatility, ACAD or ZYME? ACADIA Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Which has stronger earnings and valuation, ACAD or ZYME? ACADIA Pharmaceuticals has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$957.80M3.96$226.45M$1.3716.53Zymeworks$76.30M12.29-$122.69M-$1.49-9.03 SummaryACADIA Pharmaceuticals beats Zymeworks on 15 of the 17 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworks IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$937.89M$2.04B$2.26B$9.53BDividend YieldN/A13.64%2.56%4.05%P/E Ratio-9.0312.5122.0620.08Price / Sales12.292,681,058.8874.4788.77Price / CashN/A20.2026.5028.40Price / Book2.743.1542.555.80Net Income-$122.69M-$457.87M-$62.28M$259.24M7 Day PerformanceN/A0.28%0.10%0.61%1 Month PerformanceN/A2.27%2.39%11.83%1 Year PerformanceN/A8.10%9.93%16.52% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworksN/A$13.46flatN/AN/A$937.89M$76.30M-9.03460ACADACADIA Pharmaceuticals4.1105 of 5 stars$23.05-0.9%$28.13+22.0%+18.2%$3.89B$996.28M16.82510ACLXArcellx2.4502 of 5 stars$70.27+0.4%$111.23+58.3%+9.6%$3.86B$107.94M-23.5080Positive NewsSRRKScholar Rock3.77 of 5 stars$39.11-1.5%$42.67+9.1%+299.7%$3.77B$33.19M-15.46140Positive NewsVKTXViking Therapeutics4.5588 of 5 stars$33.50+0.3%$86.92+159.5%-49.7%$3.76BN/A-21.9020Trending NewsEarnings ReportAnalyst RevisionGap UpHigh Trading VolumePTCTPTC Therapeutics4.4698 of 5 stars$46.32-1.6%$65.00+40.3%+30.1%$3.73B$1.77B7.121,410News CoverageAnalyst ForecastAnalyst RevisionMLTXMoonLake Immunotherapeutics2.8342 of 5 stars$55.03-1.3%$74.50+35.4%+21.7%$3.57BN/A-23.932News CoverageAnalyst UpgradeSWTXSpringWorks Therapeutics0.6258 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230PTGXProtagonist Therapeutics1.3658 of 5 stars$53.74-0.8%$66.10+23.0%+39.7%$3.36B$434.43M71.65120Upcoming EarningsInsider TradeAAPGAscentage Pharma Group InternationalN/A$39.76+3.8%N/AN/A$3.34B$134.35M0.00600Gap UpIMVTImmunovant1.4122 of 5 stars$18.32-0.4%$36.30+98.1%-42.4%$3.15BN/A-6.69120Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies ACADIA Pharmaceuticals Alternatives Arcellx Alternatives Scholar Rock Alternatives Viking Therapeutics Alternatives PTC Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives SpringWorks Therapeutics Alternatives Protagonist Therapeutics Alternatives Ascentage Pharma Group International Alternatives Immunovant Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYME) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
